BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to BT-549 cell line is 256
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting and IF staining | NA | 0.52 | 0.456 | 29100426 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs | NA | 0.52 | 0.456 | 29262622 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs | NA | 0.52 | 0.456 | 30246563 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs | NA | 0.52 | 0.456 | 30460610 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29197410 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31296961 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31599500 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 27995747 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by FACs | NA | 0.52 | 0.456 | 29352988 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by FACs | NA | 0.52 | 0.456 | 29352988 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 30002443 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting and IF staining | NA | 0.52 | 1 | 29100426 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | Western Blotting and SFA | NA | 0.52 | 1 | 31308076 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs followed by SFA | NA | 0.52 | 1 | 33221681 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Carboplatin | FACs followed by SFA | NA | 0.52 | 1 | 33221681 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | FACs followed by SFA | NA | 0.52 | 1 | 33221681 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 1 | 35064101 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | MACs followed by SFA | NA | 0.52 | 1 | 34715882 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 1 | 35277657 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 1 | 35526049 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs | NA | 0.52 | 1 | 29262622 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs | NA | 0.52 | 1 | 30246563 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs | NA | 0.52 | 1 | 30460610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 1 | 29197410 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 1 | 31296961 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.52 | 1 | 31599500 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 1 | 27995747 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 1 | 28817737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by FACs | NA | 0.52 | 1 | 29352988 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by FACs | NA | 0.52 | 1 | 29352988 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.52 | 1 | 30002443 |
| ACBD3 | 15453 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | RT-PCR and Western Blotting followed by SP assay and SFA | NA | 0.48 | 0.0032 | 29307786 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33090711 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33090711 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | IF staining followed by SFA | NA | 0.48 | 0.5461 | 34889737 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 35064101 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | RT-PCR | NA | 0.48 | 0.5461 | 29262622 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33090711 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33090711 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.48 | 0.6448 | 29100426 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | IF staining followed by SFA | NA | 0.48 | 0.6448 | 34889737 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 35064101 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qPCR | NA | 0.48 | 0.6448 | 35277657 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | RT-PCR | NA | 0.48 | 0.6448 | 29262622 |
| SIK2 | 21680 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0011 | 35277657 |
| CTNNB1 | 2514 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.28 | 0.0647 | 29352988 |
| CTNNB1 | 2514 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.28 | 0.0647 | 29352988 |
| MYC | 7553 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.28 | 0.1304 | 29352988 |
| MYC | 7553 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.28 | 0.1304 | 29352988 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | Western Blotting and SFA | NA | 0.28 | 0.684 | 31308076 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | qRT-PCR | NA | 0.28 | 0.684 | 33090711 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.684 | 33090711 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.684 | 30038266 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.684 | 30038266 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | ALDEFLUOR assay followed by SFA | NA | 0.28 | 0.684 | 33221681 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Carboplatin | ALDEFLUOR assay followed by SFA | NA | 0.28 | 0.684 | 33221681 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | ALDEFLUOR assay followed by SFA | NA | 0.28 | 0.684 | 33221681 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.28 | 0.684 | 33674749 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.28 | 0.684 | 35064101 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 33510281 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 35277657 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | ALDEFLUOR assay | NA | 0.28 | 0.684 | 29197410 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | ALDEFLUOR assay | NA | 0.28 | 0.684 | 30460610 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | ALDEFLUOR assay and SFA | NA | 0.28 | 0.684 | 31296961 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.28 | 0.684 | 28817737 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 28817737 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 29352988 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 29352988 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | Western Blotting and SFA | NA | 0.28 | 0.1135 | 31308076 |
| BMP2 | 1069 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0042 | 34277708 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0647 | 29100426 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0891 | 29287960 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | qRT-PCR | NA | 0.28 | 0.0891 | 33090711 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0891 | 33090711 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0891 | 30038266 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0891 | 30038266 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.1304 | 29287960 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | IF staining followed by SFA | NA | 0.28 | 0.1304 | 34889737 |
| NOTCH1 | 7881 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0477 | 34277708 |
| NOTCH2 | 7882 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0117 | 34277708 |
| NOTCH2 | 7882 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0117 | 29100426 |
| RAD50 | 9816 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33090711 |
| RAD50 | 9816 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | Western Blotting | NA | 0.28 | 0.0021 | 33090711 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.5695 | 29100426 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | Western Blotting and SFA | NA | 0.28 | 0.5695 | 31308076 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | IF staining followed by SFA | NA | 0.28 | 0.5695 | 34889737 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | qRT-PCR | NA | 0.28 | 0.5695 | 33090711 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA and qRT-PCR | NA | 0.28 | 0.5695 | 35064101 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qPCR | NA | 0.28 | 0.5695 | 35277657 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.5695 | 33090711 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | RT-PCR | NA | 0.28 | 0.5695 | 29262622 |
| TWIST1 | 12428 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | Western Blotting | NA | 0.28 | 0.0191 | 34277708 |
| TWIST1 | 12428 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Paclitaxel | Western Blotting and SFA | NA | 0.28 | 0.0191 | 31308076 |
| AKT1 | 391 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0074 | 29352988 |
| AKT1 | 391 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0074 | 29352988 |
| AKT2 | 392 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| AKT2 | 392 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| BRAF | 1097 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| BRAF | 1097 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| CAV2 | 1528 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0074 | 29352988 |
| CAV2 | 1528 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0074 | 29352988 |
| CBL | 1541 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| CBL | 1541 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| CSK | 2444 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| CSK | 2444 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| EGFR | 3236 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0074 | 29352988 |
| EGFR | 3236 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0074 | 29352988 |
| ELK1 | 3321 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| ELK1 | 3321 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| EPS8 | 3420 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| EPS8 | 3420 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| GAB1 | 4066 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| GAB1 | 4066 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| GRB2 | 4566 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| GRB2 | 4566 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| HRAS | 5173 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| HRAS | 5173 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| IKBKB | 5960 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| IKBKB | 5960 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| IKBKG | 5961 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| IKBKG | 5961 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| JAK1 | 6190 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| JAK1 | 6190 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| JAK2 | 6192 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 29352988 |
| JAK2 | 6192 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0053 | 29352988 |
| JUN | 6204 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 29352988 |
| JUN | 6204 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0053 | 29352988 |
| MAP2K2 | 6842 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| MAP2K2 | 6842 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| MAP2K4 | 6844 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| MAP2K4 | 6844 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| MAP2K7 | 6847 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| MAP2K7 | 6847 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| MAP3K1 | 6848 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| MAP3K1 | 6848 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| MAPK1 | 6871 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| MAPK1 | 6871 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| MAPK10 | 6872 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| MAPK10 | 6872 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| MAPK3 | 6877 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 29352988 |
| MAPK3 | 6877 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Up | 0.24 | 0.0032 | 29352988 |
| MAPK8 | 6881 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| MAPK8 | 6881 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| MRAS | 7227 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| MRAS | 7227 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| MUC1 | 7508 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 29352988 |
| MUC1 | 7508 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0042 | 29352988 |
| NCK1 | 7664 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| NCK1 | 7664 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| NFKB1 | 7794 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0064 | 29352988 |
| NFKB1 | 7794 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0064 | 29352988 |
| NFKB2 | 7795 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| NFKB2 | 7795 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| NRAS | 7989 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| NRAS | 7989 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| PAK1 | 8590 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| PAK1 | 8590 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| PDPK1 | 8816 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| PDPK1 | 8816 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| PIK3C2A | 8971 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| PIK3C2A | 8971 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| PIK3CA | 8975 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| PIK3CA | 8975 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| PIK3CD | 8977 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| PIK3CD | 8977 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| PIK3R1 | 8979 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 29352988 |
| PIK3R1 | 8979 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0042 | 29352988 |
| PIK3R2 | 8980 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| PIK3R2 | 8980 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| PLCG1 | 9065 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| PLCG1 | 9065 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| PRKCD | 9399 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| PRKCD | 9399 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| PRKCE | 9401 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| PRKCE | 9401 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| PRKCZ | 9412 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 29352988 |
| PRKCZ | 9412 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Up | 0.24 | 0.0011 | 29352988 |
| RAB5A | 9783 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| RAB5A | 9783 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| RAC1 | 9801 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| RAC1 | 9801 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| RAF1 | 9829 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| RAF1 | 9829 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| RASA1 | 9871 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| RASA1 | 9871 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| REL | 9954 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| REL | 9954 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| RELA | 9955 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| RELA | 9955 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| RELB | 9956 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| RELB | 9956 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| RHOA | 667 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| RHOA | 667 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| RHOB | 668 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 29352988 |
| RHOB | 668 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0042 | 29352988 |
| RHOC | 669 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| RHOC | 669 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| RHOD | 670 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| RHOD | 670 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| RHOG | 672 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| RHOG | 672 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| RND3 | 671 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| RRAS | 10447 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| RRAS | 10447 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| RRAS2 | 17271 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29352988 |
| RRAS2 | 17271 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0011 | 29352988 |
| SOS1 | 11187 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| SOS1 | 11187 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| SOS2 | 11188 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| SOS2 | 11188 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| SRC | 11283 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 29352988 |
| SRC | 11283 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0032 | 29352988 |
| STAT1 | 11362 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| STAT1 | 11362 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| STAT3 | 11364 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0223 | 29352988 |
| VAV2 | 12658 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| VAV2 | 12658 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| VAV3 | 12659 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29352988 |
| VAV3 | 12659 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.24 | 0.0021 | 29352988 |
| STAT3 | 11364 | HTM/LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay and qRT-PCR | Up | 0.24 | 0.0223 | 29352988 |
| LINC01638 | 52425 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | qRT-PCR followed by SFA and Migration Invasion assay | NA | 0.2 | 0.0011 | 30002443 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Cyclophosphamide | qRT-PCR | NA | 0.2 | 0.7582 | 33090711 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.7582 | 33090711 |
| WASF3 | 12734 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | qRT-PCR followed by SFA and Migration assay | NA | 0.2 | 0.0011 | 29262622 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | FACs followed by SFA | NA | 0.12 | 0.456 | 35064101 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | MACs followed by SFA | NA | 0.12 | 0.456 | 34715882 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.12 | 0.456 | 35277657 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | NA | SFA followed by FACs | NA | 0.12 | 0.456 | 35526049 |
| AKT3 | 393 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| ARAF | 646 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| CAV1 | 1527 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0117 | 29352988 |
| CDH1 | 1748 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0053 | 29352988 |
| CHUK | 1974 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| DIRAS3 | 687 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| DOK2 | 2991 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| EGF | 3229 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| ERBB2 | 3430 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0074 | 29352988 |
| FOS | 3796 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.04 | 0.0053 | 29352988 |
| IKBKE | 14552 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| KRAS | 6407 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| MAP2K1 | 6840 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| MAPK9 | 6886 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| PIK3C2B | 8972 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0032 | 29352988 |
| PIK3CB | 8976 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| PRKCA | 9393 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0042 | 29352988 |
| PRKCB | 9395 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0032 | 29352988 |
| PRKCG | 9402 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| PRKCQ | 9410 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| PTK2 | 9611 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0032 | 29352988 |
| PXN | 9718 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |
| RCL1 | 17687 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | Down | 0.04 | 0.0011 | 29352988 |
| SHC1 | 10840 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| SHC3 | 18181 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0021 | 29352988 |
| VAV1 | 12657 | HTM | Triple Negative Breast Cancer | Ductal Carcinoma | BT-549 | Doxorubicin | FACs for CSC marker followed by SFA and PCR array assay | NA | 0.04 | 0.0011 | 29352988 |